Business, energy, technology, markets and global industry news from Business News Today

APEX study

PharmaDeviceNews APEX study
Representative image showing a clinician reviewing joint health with a patient, reflecting Johnson & Johnson’s Tremfya FDA label expansion for structural joint damage inhibition in active psoriatic arthritis.
Pharma & Biotech

Can Tremfya turn radiographic evidence into a commercial advantage for Johnson & Johnson?

Find out how Johnson & Johnson’s Tremfya label expansion could reshape IL-23 competition in psoriatic arthritis care.

Read More
Representative image: An ophthalmology clinic scene showing retinal imaging and eye examination technology, reflecting Kodiak Sciences’ KSI-101 clinical data in macular edema secondary to inflammation and the growing role of biologics in inflammatory retinal disease treatment.
Pharma & Biotech

Could Kodiak’s KSI-101 become the first real biologic challenger in inflammatory eye disease?

Steroids still dominate MESI care. Kodiak’s KSI-101 may test whether local biologics can change inflammatory retina treatment.

Read More